Department of Dermatology, University of California, San Francisco, CA 94143, USA.
Immunotherapy. 2012 Sep;4(9):939-45. doi: 10.2217/imt.12.93.
Actinic keratoses are common in older individuals and topical immunotherapy is an important treatment when multiple lesions are present. To assess the efficacy of 5-fluorouracil in treating actinic keratoses, a systematic review of randomized, vehicle-controlled trials was performed. Percentages of 5-fluorouracil and vehicle responders were determined by absolute clearance and mean percent reduction in lesion count. Four trials with 399 and 269 participants in active treatment and vehicle groups, respectively, were evaluated. After 4 weeks of treatment, total clearance and mean lesion count reduction were 52.6 and 90.2% in the treatment group versus 0.85 and 28.3% in the vehicle group, respectively. Topical 5-fluorouracil is efficacious in treating actinic keratoses; however, vehicle responses warrant further investigation of study design and disease severity scales.
光化性角化病常见于老年人，当存在多个病变时，局部免疫治疗是一种重要的治疗方法。为了评估 5-氟尿嘧啶治疗光化性角化病的疗效，对随机、对照试验进行了系统评价。通过绝对清除率和病变计数的平均百分比减少来确定 5-氟尿嘧啶和载体应答者的百分比。评估了 4 项试验，分别有 399 名和 269 名参与者在活性治疗组和载体组中。治疗 4 周后，治疗组的总清除率和平均病变计数减少分别为 52.6%和 90.2%，而载体组分别为 0.85%和 28.3%。局部 5-氟尿嘧啶治疗光化性角化病有效；然而，载体反应需要进一步研究研究设计和疾病严重程度量表。
